



Original Article

Analysis of the mutations in exon 10 of *MEFV* gene in patients with premature coronary heart disease in west Azerbaijan province of Iran

Morteza Bagheri¹, Kamal Khadem-Vatani^{2*}, Mir Hossein Seyed Mohammad Zad², Isa Abdi Rad¹, Behzad Rahimi², Alireza Rostamzadeh², Mojtaba Godarzi², Shabnam Ashena²

¹Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran

²Seyyed-al Shohada University Hospital, Urmia University of Medical Sciences, Urmia, Iran

Article info

Article History:

Received: 15 May 2017

Accepted: 18 February 2018

published: 17 March 2018

Keywords:

MEFV

PCHD

Mutations

Abstract

Introduction: Premature coronary heart disease (PCHD) affects public health and leads to death. PCHD has several genetic and environmental risk factors. The aim of this study was to analysis of the mutations in exon 10 of *MEFV* gene in patients with PCHD in West Azerbaijan province of Iran.

Methods: Totally 41 PCHD patients who were admitted to the cardiology unit of Sayedshohada hospital (Urmia, Iran) enrolled in the study. Selection of the patients was done based on the strict criteria, that is, who had a minimum of one angiographically documented coronary artery with the stenosis of 50%. Mutations in exon 10 of *MEFV* gene were found by direct sequencing.

Results: V726A, M680I, K695R, and A744S mutations with 2.44%, 1.22%, 1.22%, and 1.22%, allelic frequency were found, respectively. Five patients (12.2%) with PCHD carried at least one mutated *MEFV* allele. Heterozygote V726A was the most frequent mutation among tested cases (4.88%), followed by heterozygote M680I, heterozygote K695R, and heterozygote A744S.

Conclusion: The results of the present study imply that the frequency of the *MEFV* gene exon 10 is significantly high in PCHD patients. This is the first report in its own kind in clinically diagnosed PCHD patients of Iranian Azeri Turkish population.

Please cite this article as: Bagheri M, Kamal Khadem-Vatani K, Seyed Mohammad Zad MH, Abdi Rad I, Rahimi B, Rostamzadeh A, Godarzi M, Ashena S. Analysis of the mutations in exon 10 of *MEFV* gene in patients with premature coronary heart disease in west Azerbaijan province of Iran. *J Cardiovasc Thorac Res* 2018;10(1):20-23. doi: 10.15171/jcvtr.2018.03.

Introduction

Premature Coronary Heart Disease (PCHD), also defined as premature coronary artery disease (PCAD) affects public health and leads to death.¹ CAD has several genetic and environmental risk factors. The prevalence of CAD became increased in developing countries such as Iran.¹ CAD is responsible for approximately 50 percent of all deaths per year in Iran.¹ CAD as a multifactorial disease is influenced by gender. CAD prevalence is about 6.9% and 6% in men and women, respectively.² Several traditional risk factors influences the CAD related disability and mortality such as obesity, end stage renal disease, diabetes mellitus, smoking, dyslipidemia, physical inactivity, metabolic syndrome, family history of PCAD and systemic anatomic vascular disorders.^{3,4} The pathogenesis of CAD is poorly understood.³ CAD is a common form of coronary atherosclerosis. CAD is the result of creation of atherosclerotic plaques within coronary vessels that leads to a heart attack or unexpected

cardiac-fatality.⁴ Reduction of coronary artery flow is under the impact of impediment severity and the rapidity of its expansion.⁵ It may occur at any time of life, but most commonly happens in young asymptomatic individuals.⁶ Management of CAD is dependent on the identification of genetic and environmental factors such as gene-gene and gene-environment interactions.⁷ There is an interest to find new biomarkers that can judge CAD risk and therapeutic efficiency. Large bodies of biomarkers have been evaluated in CAD such as circulating and inflammation-associated microRNAs⁸, Urinary proteomic biomarkers,⁹ and inflammatory biomarkers.¹⁰ Familial Mediterranean fever (FMF) as a multisystem disease is an autosomal recessive disease that predominantly influences various tissues of the body such as gastrointestinal tract, heart, testis, liver, spleen, lungs, and kidneys. Clinical presentation of FMF includes abdominal pain, muscle pain, rash and fever, amyloidosis, vasculitis, and infertility.¹¹ The *MEFV* gene is

*Corresponding Author: Kamal Khadem-Vatani, Email: khademvatan2002@yahoo.com

© 2018 The Author (s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

mapped on the short arm of chromosome 16 (16p13.3) and has 10 exons and encodes pyrin (marenostriin) with 781 amino acid.¹² The role of pyrin was not well understood, but it is supposed that to act as anti-inflammatory mediator.¹³ Basar et al revealed for the first time that *MEFV* mutations could be as a risk factor for early CHD.¹⁴ More than 180 mutations have been recognized in the *MEFV* gene,¹⁵ but CHD-associated *MEFV* gene mutations were not studied in Iranian population. Mutations in exon 10 of *MEFV* gene has clinical significance in our population.¹⁶ The aim of this study was to analyze the mutations in exon 10 of *MEFV* gene in patients with PCHD in West Azerbaijan province of Iran.

Materials and Methods

Totally 41 CAD patients who were admitted in the cardiology unit of Sayedoshohada hospital (Urmia, Iran) enrolled in the study. This study was done at Urmia University of Medical Sciences (Urmia, Iran). PCHD was identified with an age of onset of CHD ≤ 55 years in males and ≤ 65 years in females.¹⁷ Selection of the patients was done based on strict criteria, that is, who had a minimum of one angiographically documented coronary artery with the stenosis of 50%.¹⁸ Diagnosis of CAD was confirmed by electrocardiography, coronary angiography, and echocardiography.¹⁸ None of our cases was clinically diagnosed with FMF. Exclusion criteria were high blood pressure, diabetes, and smoking. Patients were evaluated by an expert cardiologists based on the accepted criteria. Each patient was informed about the contents and aims of the study. 2-3 ml blood sample were obtained in EDTA-containing tubes for extraction of DNA. Blood samples were preserved in -20°C till DNA extraction. DNA extraction was carried out using standard "salting out" method,¹⁹ and then was preserved in -80°C till PCR. In our samples, the purity of DNA extracts was confirmed by measuring absorption at 260 nm and 280 nm in a Biophotometer (Ependorf AG, Germany). Mutations in exon 10 were found by direct sequencing of PCR products using two sets of primers including *MEFV* F: 5'-ccc atg gac ccc tac cta gg-3' and *MEFV* R: 5'-aag aga gat gca gtg ttg ggc-3'.¹⁴ The PCR program was as: 94°C for 4 minutes; 30 cycles: 94°C for 1 minute and 58°C for 30 seconds. PCR reactions were carried out in 25 μL solution: 100 ng of DNA, 1x reaction buffer 5 pmol of each primer, 200 μmol of each dNTPs, 0.2 unit of Taq DNA polymerase, and 1.5 mmol MgCl_2 . PCR products were analyzed via electrophoresis on 2% agarose gel stained with CinnaGen DNA safe Stain (CinnaGen Co. Tehran, Iran). Presence of a 617(bp) fragment was monitored by UV transilluminator. Subsequently direct sequencing of the PCR products was carried out in an ABI 730XL DNA analyzer (Applied Biosystems). Chromas Lite version 2.1.1 (2012) was used for chromatogram visualization of sequenced DNA fragments (Chromas Lite version 2.1 (2012), Technelysium Pty Ltd, South Brisbane, Queensland, Australia). Descriptive statistics were used to

report the frequency of the mutations in this study.

Results

The findings of this study are shown in Figures 1-4. Five patients (12.2%) with PCHD carried at least one mutated *MEFV* allele. Heterozygote V726A was the most frequent mutation among tested cases (4.88%),




Figure 1. Schematic representation of the V726A mutation in exon 10 of *MEFV* gene. Red color graph represent the T allele and blue color graph represent the C allele in suspected DNA locus (c.2177T>C).




Figure 2. Schematic representation of the M680I mutation in exon 10 of *MEFV* gene. Black color graph represent the G allele and blue color graph represent the C allele in suspected DNA locus (c.2040G>C).




Figure 3. Schematic representation of the K695R mutation in exon 10 of *MEFV* gene. Green color graph represent the A allele and black color graph represent the G allele in suspected DNA locus (c.2084A>G).




Figure 4. Schematic representation of the A744S mutation in exon 10 of *MEFV* gene. Black color graph represent the G allele and red color graph represent the T allele in suspected DNA locus (c.2230G>T).

Table 1. Studied mutations and the frequencies of cases and chromosomes with at least one mutation in this study

Protein Mutation	Nucleotide Mutation	Amino Acid Change	Genotype	Cases (%)	Chromosomes (%)
V726A	c.2177T>C	V[Val]/A[Ala]	Heterozygote	2(4.88)	2(2.44)
M680I	c.2040G>C	M[Met]/I[Ile]	Heterozygote	1(2.44)	1(1.22)
K695R	c.2084A>G	K[Lys]/R[Arg]	Heterozygote	1(2.44)	1(1.22)
A744S	c.2230G>T	A[Ala]/S[Ser]	Heterozygote	1(2.44)	1(1.22)

followed by heterozygote M680I, heterozygote K695R, and heterozygote A744S. The frequencies of cases and chromosomes with at least one mutation are reported in Table 1. The average age of our patients was 45.25 ± 5.28 .

Discussion

CAD is a leading killer but preventable by reduction of risk factors, so, the risk factors of CAD should be determined.²⁰ The total risk of CAD is dependent on the interaction of genetic and environmental risk factors. Most of these risk factors appear to promote the CAD through atherosclerosis.²¹ Atherosclerosis is the result of chronic inflammation and is accelerated by risk factors such as hypertension, hyperlipidemia particularly low-density lipoproteins (LDL), type 2 diabetes mellitus, obesity, cigarette smoking, and genetic susceptibility²¹. Some risk factors are under genetic control and a positive family history is identified as an important predictor of CAD.²² The genetic factors are involved in 40%–50% of CAD cases, and several studies showed many genetic loci that predispose the patients to CAD.²² Also, large bodies of single-nucleotide polymorphisms (SNPs) have been tested in human diseases.^{13,23-27} In coronary atherosclerosis, pathophysiological changes are slow and lead to intimal thickening and formation of atherosclerotic plaques.²⁸ In coronary vessels, the immune response contains increased expression of adhesion molecules and inflammatory cytokines.²⁹ These processes lead to the development of plaques and unexpected progression of plaques and variable clinical findings.³⁰ Numerous genetic factors influence the CAD susceptibility with different effect size, and determination of genetic biomarkers such as CAD-associated RNA-based biomarkers can provide novel methods for the prediction and management of CAD.³¹ In this regard, role of several cytokines (such as IL-17, IL-18) are identified in endothelial dysfunction, oxidative stress and over-production of adhesion molecules.^{32,33} The focus of this study was to evaluate the role of *MEFV* gene mutations on the exon 10 in the PCHD patients. In this study, V726A, M680I, K695R, and A744S mutations were found. The results of the present study were in agreement with Basar et al, and imply that the frequency of *MEFV* mutations have significantly increased in the PCHD patients. Bonyadi et al determined the *MEFV* gene mutations among Iranian Azeri Turkish general population (the same ethnic group as of our study) that indicated none of tested individuals were carriers

for M694V, M694I, and M680I, whereas 1.75% of the chromosomes carried the V726A mutations. K695R and A744S mutations are less common.³⁴ In our study, 12.2% of cases had a mutation in exon 10 of *MEFV* gene, which is in agreement with Basar et al. M680I, K695R, and A744S mutations, which were not found or found with very low frequency in the general population, account for 3.66% of chromosomes with at least one mutation. Present study has some limitations including the small number of tested patients, poor quality of registry data regarding family medical history, other contributing risk factors such as psychosocial factors, stress and physical activity. Future study, with large number of samples, is essential to confirm these findings.

Conclusion

The present study is the first report in its own kind and implies that the frequencies of *MEFV* mutations on the exon 10 are increased significantly in PCHD patients.

Competing interests

The authors declare that they have no competing interests.

Ethical approval

Urmia University of Medical Sciences Research Ethics Committee has approved all stage of this study (Ir.umsu.rec.1394.138).

Acknowledgments

This study was financially supported by Urmia Medical Science University (Grant No: 1747).

We are grateful to the participants, for providing the samples, and to medical staff of Sayedshohada hospital (Urmia, Iran) for collecting the samples.

References

- Hatmai ZN, Tahvildari S, Motlag AG, Kashani. Prevalence of coronary artery disease risk factors in Iran: A population based survey. *BMC Cardiovasc Disord* 2007; 7: 32.
- Bagheri M, Rad IA. Analysis of the Most Common Three *MEFV* Mutations in 630 Patients with Familial Mediterranean Fever in Iranian Azeri Turkish Population. *Maedica (Buchar)* 2017; 12(3):169-173.
- Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. *JAMA* 2011;306(19):2120-7. doi: 10.1001/jama.2011.1654.
- Rasmi Y, Bagheri M, Faramarz-Gaznagh S, Nemati M, Khadem-Ansari MH, Saboory E, et al. Transcriptional activity of tumor necrosis factor-alpha gene in peripheral blood mononuclear cells in patients with coronary slow

- flow. **ARYA Atheroscler** 2017; 13(4):196-201.
5. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. **Br J Pharmacol** 2008; 153(8):1589-601. doi: 10.1038/sj.bjp.0707673.
 6. Ha EJ, Kim Y, Cheung JY, Shim SS. Coronary artery disease in asymptomatic young adults: its prevalence according to coronary artery disease risk stratification and the CT characteristics. **Korean J Radiol** 2010;11(4):425-32. doi: 10.3348/kjr.2010.11.4.425.
 7. Padmanabhan S, Hastie C, Prabhakaran D, Dominczak AF. Genomic approaches to coronary artery disease. **Indian J Med Res** 2010; 132:567-78.
 8. Li S, Lee C, Song J, Lu C, Liu J, Cui Y, et al. Circulating microRNAs as potential biomarkers for coronary plaque rupture. **Oncotarget** 2017;8(29):48145-6. doi: 10.18632/oncotarget.18308.
 9. Röthlisberger S, Pedroza-Diaz J. Urine protein biomarkers for detection of cardiovascular disease and their use for the clinic. **Expert Rev Proteomics** 2017;14(12):1091-3. doi: 10.1080/14789450.2017.1394188.
 10. Mirzaei H, Ferns GA, Avon A, Mobarhan MG. Cytokines and MicroRNA in Coronary Artery Disease. **Adv Clin Chem** 2017;82:47-70. doi: 10.1016/bs.acc.2017.06.004.
 11. Cekin N, Akyurek ME, Pinarbasi E, Ozen F. MEFV mutations and their relation to major clinical symptoms of Familial Mediterranean Fever. **Gene** 2017;626:9-13. doi: 10.1016/j.gene.2017.05.013.
 12. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. **Eur J Hum Genet** 2001;9(7):473-83.
 13. Manukyan G, Aminov R. Update on Pypin Functions and Mechanisms of Familial Mediterranean Fever. **Front Microbiol** 2016;7:456. doi: 10.3389/fmicb.2016.00456.
 14. Basar N, Kısacık B, Ercan S, Pehlivan Y, Yılmaz S, Simsek I, et al. Familial Mediterranean fever gene mutations as a risk factor for early coronary artery disease. **Int J Rheum Dis** 2014 Apr 7. doi: 10.1111/1756-185X.12356.
 15. Bonyadi M, Niaei G, Abdolmohammadi R. Assessment of MEFV Gene Mutations in Exon 10 in Familial Mediterranean Fever Patients from Iranian Azeri and Turkish Population. **Iran J Public Health** 2016;45(1):112-3.
 16. Nikibakhsh AA, Houshmand M, Bagheri M, Zadeh HM, Rad IA. MEFV gene mutations (M694V, V726A, M680I, and A744S) in Iranian children with Henoch-Schönlein purpura. **Pneumologia** 2012;61(2):84-7.
 17. Che J, Li G, Shao Y, Niu H, Shi Y. An analysis of the risk factors for premature coronary artery disease in young and middle-age Chinese patients with hypertension. **Exp Clin Cardiol** 2013; 18(2):89-92.
 18. Jiangping S, Zhe Z, Wei W, Yunhu S, Jie H, Hongyue W, et al. Assessment of coronary artery stenosis by coronary angiography: a head-to-head comparison with pathological coronary artery anatomy. **Circ Cardiovasc Interv** 2013;6(3):262-8. doi: 10.1161/CIRCINTERVENTIONS.112.000205.
 19. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. **Nucleic Acids Res** 1988; 16:1215.
 20. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. **BMJ** 2003;326(7404):1419.
 21. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. **J Atheroscler Thromb** 2003;10(2):63-71.
 22. Ozaki K, Tanaka T. Molecular genetics of coronary artery disease. **J Hum Genet** 2016;61(1):71-7. doi: 10.1038/jhg.2015.70.
 23. IA Rad, M Bagheri, MH Rahimi-Rad, Z Moradi. IFN- γ +874 and IL-4 -590 polymorphisms and asthma susceptibility in North West of Iran. **Tanaffos** 2010;9(4):22-27.
 24. Omrani MD, Bagheri M, Bushehri B, Azizi F, Anoshae MR. The association of TGF- β 1 codon 10 polymorphism with suicide behavior. **Am J Med Genet B Neuropsychiatr Genet** 2012;159B(7):772-5. doi: 10.1002/ajmg.b.32082.
 25. Bagheri M, Abdi Rad I, Hosseini Jazani N, Nanbakhsh F. Vitamin D Receptor TaqI Gene Variant in Exon 9 and Polycystic Ovary Syndrome Risk. **Int J Fertil Steril** 2013;7(2):116-21.
 26. Omrani MD, Bazargani S, Bageri M. Interleukin-10, interferon-g and tumor necrosis factor-a genes variation in prostate cancer and benign prostatic hyperplasia. **Curr Urol** 2009;2:175-80.
 27. Abdi Rad I, Bagheri M. Angiotensin-converting enzyme insertion/deletion gene polymorphism in general population of west Azarbaijan, Iran. **Iran J Kidney Dis** 2011;5(2):86-92.
 28. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. **Circ Res** 2014;114(12):1852-66. doi: 10.1161/CIRCRESAHA.114.302721.
 29. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. **Biochem Pharmacol** 2009;78(6):539-52. doi: 10.1016/j.bcp.2009.04.029.
 30. Riccioni G, De Santis A, Cerasa V, Menna V, Di Ilio C, Schiavone C, et al. Atherosclerotic plaque formation and risk factors. **Int J Immunopathol Pharmacol** 2003;16(1):25-31.
 31. Roberts R, Stewart AF. Genes and coronary artery disease: where are we? **J Am Coll Cardiol** 2012;60(18):1715-21.
 32. Haznedaroglu S, Oztürk MA, Sancak B, Goker B, Onat AM, Bukan N, et al. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. **Clin Exp Rheumatol** 2005; 23(4 Suppl 38):S77-80.
 33. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schönbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascularendothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. **J Exp Med** 2002;195(2):245-57.
 34. Bonyadi M, Esmaeili M, Karimi A, Dastgiri S. Common Mediterranean fever gene mutations in the Azeri Turkish population of Iran. **Genet Test Mol Biomarkers** 2010;14(1):149-51. doi: 10.1089/gtmb.2009.0087.